Compare SCNX & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNX | NAII |
|---|---|---|
| Founded | 2010 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 15.8M |
| IPO Year | 2019 | 1995 |
| Metric | SCNX | NAII |
|---|---|---|
| Price | $0.36 | $2.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 771.9K | 19.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,831,778.00 | ★ $132,437,000.00 |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.72 | 8.60 |
| 52 Week Low | $0.24 | $1.98 |
| 52 Week High | $2.60 | $4.96 |
| Indicator | SCNX | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 38.85 |
| Support Level | $0.30 | N/A |
| Resistance Level | $0.43 | $2.83 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 17.56 | 8.70 |
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.